Circulating Tumor Cells

Faculty
SUPPORTED BY AN UNCONDITIONAL EDUCATIONAL
SPONSORSHIP FROM
Updating on
Circulating
Tumor Cells
Aieta Michele, IRCCS-CROB, Rionero in Vulture (PZ), Italy
Amadori Alberto, IOV-IRCCS, Padova, Italy
Basso Umberto, IOV-IRCCS, Padova, Italy
Bonciarelli Giorgio, Direttore U.O.C. Oncologia Medica, Este, Italy
in cancer patients
management
Buonocore Caterina, Agenzia Promozione della Ricerca Europea, Roma, Italy
2 nd
20
14
Chiarion-Sileni Vanna, IOV-IRCCS, Padova, Italy
Conte PierFranco, University of Padova, IOV-IRCCS, Padova, Italy
be
r2
Cristofanilli Massimo, Jefferson Breast Care Center at the Kimmel Cancer Center
(KCC) and Thomas Jefferson University and Hospitals, Philadelphia, USA
Grisanti Salvatore, Spedali Civili di Brescia, Italy
Ijzerman Maarten, HTSR University of Twente, Netherlands
Munzone Elisabetta, IEO, Milano, Italy
Opocher Giuseppe, Istituto Oncologico Veneto IRCCS, Padova, Italy
ECM - CONTINUING MEDICAL EDUCATION (C.M.E.)
FOR ITALIAN PARTECIPANTS ONLY
Terstappen Leon W. M. M., HTSR University of Twente, Netherlands
3 C.M.E. credits have been assigned for: biologist, pharmasist, medical
technician biomedical laboratory and medical radiology, doctor (all
medical disciplines), nurse.
Zagonel Vittorina, IOV-IRCCS, Padova, Italy
CONFERENCE VENUE
Zamarchi Rita, IOV-IRCCS, Padova, Italy
Auditorium San Gaetano
Via Altinate, 71- Padova
Pantano Francesco, Università Campus Bio-Medico, Roma, Italy
y,
S
There is no registration fee, but advanced registration is required.
All registration must be submitted online:
www.events-communication.net/circulatingtumorcells
Official language is English.
da
Gennari Alessandra, Galliera Hospital, Genova, Italy
on
REGISTRATION
M
Gazzaniga Paola, Università La Sapienza, Roma, Italy
ep
te
m
Foroni Chiara, Istituti Ospitalieri Cremona, Italy
ORGANIZING SECRETARIAT
Events
congress&communication
Via Mantegna, 1 - 60019 Senigallia (AN)
Tel +39 071.7930220 - Fax +39 071.9252094
[email protected]
www.events-communication.net
Auditorium San Gaetano
p
INTRODUCTION
The meeting aims to update the participants on the use of the CTC assay in
cancer patients, ten years later the first published report on its prognostic
and predictive value in metastatic breast cancer.
To this purpose, we invited the speakers among the Italians who have
already used the CTCs in different cancers.
Furthermore, we will open the seminar with talks by the greatest CTC
experts to give an international-scale profile to the conference.
The focus of the meeting will be as following:
1) To sharing the knowledge of European metanalysis results on the CTC
use in MBC;
2) To involve all stakeholders in debating the use of CTC assay as
companion diagnostic, including: the health professionals, the Health
Technology Assessment service of public hospitals of Veneto region, the
Regional authorities that establish the reimbursement of new diagnostic
tests, the regulatory authorities of the Italian drug agency;
3) To present the opportunities offered by the European financial support
(Horizon 2020) toward proposals of translational medicine for cancer
patients that include the CTC assay or the study of circulating compartment.
Through this initiative, we expect to increase the network of our research
collaborations around the CTC theme.
ORGANIZING COMMITEE
Dr.ssa Rita Zamarchi
U.O.C. Immunologia e Diagnostica
Molecolare Oncologica
IOV-IRCCS Padova
r
o
g
8.30
Participants’ Registration
9.00 Welcome address
General Manager IOV-IRCCS
Scientific Director IOV-IRCCS
1st SESSION
CHAIRS: A. Amadori, G. Opocher
9.15 CTCs and breast cancer ten years later
M. Cristofanilli
9:45
The biomarkers in the target drug era TBD
(an expert of AIFA, the Italian Agency for drug approval)
10.15
New perspectives in CTCs investigation
L. W. M. M. Terstappen
r
10.45 Discussion
11.00
Coffee break
2nd SESSION
CHAIRS: V. Zagonel, R. Zamarchi
11.15
Employ of CTCs in clinical trials: the Myme study experience
A. Gennari
11.35
RANK expression on CTCs in metastatic breast cancer
F. Pantano
11.55 Prognostic value of CTC detection in high-risk Non-Muscle
Invasive Bladder Cancer
P. Gazzaniga
12.15
Economic impact of news biomarkers in the management
of cancer patients
M. Ijzerman
12.45 Discussion
13.15
Lunch
a
m
m
a
3rd SESSION
CHAIRS: V. Chiarion-Sileni, P. Conte
14.15
A case report: detection of EML4-ALK positive CTCs in an
adenocarcinoma of lung
M. Aieta
14.30 A case report: CTC detection in a locally advanced head and neck cancer
S. Grisanti
14.45 A case report: CTC use in adjuvant setting
E. Munzone
15.00 A case report: CTCs’ changes in a MBC patients under
zoledronic acid (ZA)
C. Foroni
15.15
A case report: the detection of CTCs anticipates the
knowledges of disease recurrence in MBC
G. Bonciarelli
15.30 A case report: changes of CTC and CEC levels in a
mRCC cancer patient under pazopanib treatment
U. Basso
15.45 A case report: detection of KIT mutation in
Circulating Melanoma Cells (CMCs)
V. Chiarion-Sileni
16.00 New topic for greater opportunities in drafting proposals
for NCP Horizon 2020 Health programme
C. Buonocore
16.30 Round table with the experts
V. Chiarion-Sileni, P. F. Conte, M. Cristofanilli,
P. Gazzaniga, A. Gennari, F. Pantano
17.30 Closing remarks and ECM test

Download Report